Mucolipidosis type IV (MLIV) is a lysosomal storage disease exhibiting progressive intellectual disability, motor impairment, and premature death. There is currently no cure or corrective treatment. The disease results from mutations in the gene encoding mucolipin-1, a transient receptor potential channel believed to play a key role in lysosomal calcium egress. Loss of mucolipin-1 and subsequent defects lead to a host of cellular aberrations, including accumulation of glycosphingolipids (GSLs) in neurons and other cell types, microgliosis and, as reported here, cerebellar Purkinje cell loss. Several studies have demonstrated that N-butyldeoxynojirimycin (NB-DNJ, also known as miglustat), an inhibitor of the enzyme glucosylceramide synthase (GCS), successfully delays the onset of motor deficits, improves longevity, and rescues some of the cerebellar abnormalities (e.g., Purkinje cell death) seen in another lysosomal disease known as Niemann-Pick type C (NPC). Given the similarities in pathology between MLIV and NPC, we examined whether miglustat would be efficacious in ameliorating disease progression in MLIV. Using a full mucolipin-1 knockout mouse (Mcoln1-/-), we found that early miglustat treatment delays the onset and progression of motor deficits, delays cerebellar Purkinje cell loss, and reduces cerebellar microgliosis characteristic of MLIV disease. Quantitative mass spectrometry analyses provided new data on the GSL profiles of murine MLIV brain tissue and showed that miglustat partially restored the wild type profile of white matter enriched lipids. Collectively, our findings indicate that early miglustat treatment delays the progression of clinically relevant pathology in an MLIV mouse model, and therefore supports consideration of miglustat as a therapeutic agent for MLIV disease in humans.

Center for Genomic Medicine Massachusetts General Hospital Harvard Medical School 185 Cambridge St Boston MA 02114 USA

Dominick P Purpura Dept of Neuroscience Rose F Kennedy Intellectual and Developmental Disabilities Research Center Albert Einstein College of Medicine Bronx NY 10461 USA

Institute of Inherited Metabolic Disorders 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Aerts JMFG, Hollak CEM, Boot RG, Groener JEM, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29:449–56. doi: 10.1007/s10545-006-0272-5. PubMed DOI

Altarescu G, Sun M, Moore DF, Smith JA, Wiggs EA, Solomon BI, Patronas NJ, Frei KP, Gupta S, Kaneski CR, Quarrell OW. The neurogenetics of mucolipidosis type IV 2002 PubMed

Amir N, Zlotogora J, Bach G. Mucolipidosis type IV: clinical spectrum and natural history. Pediatr Off J Am Acad Pediatr. 1987;79:956–959. PubMed

Ashe KM, Bangari D, Li L, Cabrera-Salazar Ma, Bercury SD, Nietupski JB, Cooper CGF, Aerts JMFG, Lee ER, Copeland DP, Cheng SH, Scheule RK, Marshall J. Iminosugar-Based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff Disease. J PLoS One. 2011;6 doi: 10.1371/journal.pone.0021758. PubMed DOI PMC

Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, Desnick RJ, Scheule RK, Leonard JP, Cheng SH, Marshall J. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease. Mol Med. 2015;21:389–99. doi: 10.2119/molmed.2015.00088. PubMed DOI PMC

Bach G. Mucolipin 1: endocytosis and cation channel - a review. Eur J Physiol. 2005;451:313–317. PubMed

Bach G, Cohen MM, Kohn G. Abnormal ganglioside accumulation in cultured fibroblasts from patients with Mucolipidosis IV. Biochem Biophys Res Commun. 1975;66:1483–1490. PubMed

Bargal R, Avidan N, Ben-Asher E, Olender Z, Zeigler M, Frumkin A, Raas-Rothschild A, Glusman G, Lancet D, Bach G. Identification of the gene causing mucolipidosis type IV. Nature. 2000;26:120–123. PubMed

Bargal R, Avidan N, Olender T, Ben Asher E, Zeigler M, Raas-Rothschild A, Frumkin A, Ben-Yoseph O, Friedlender Y, Lancet D, Bach G. Mucolipidosis type IV: novel MCOLN1 mutations in Jewish and non-Jewish patients and the frequency of the disease in the Ashkenazi Jewish population. Hum Mutat. 2001;17:397–402. doi: 10.1002/humu.1115. PubMed DOI

Barski JJ, Hartmann J, Rose CR, Hoebeek F, Mörl K, Noll-Hussong M, De Zeeuw CI, Konnerth A, Meyer M. Calbindin in cerebellar Purkinje cells is a critical determinant of the precision of motor coordination. J Neurosci. 2003;23:3469–77. PubMed PMC

Cheng X, Shen D, Samie M, Xu H. Mucolipins: Intracellular TRPML1-3 channels. FEBS Lett. 2010;584:2013–21. doi: 10.1016/j.febslet.2009.12.056. PubMed DOI PMC

Cox T. Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr. 2005;94:69–75. doi: 10.1080/08035320510028157. PubMed DOI

Curcio-Morelli C, Charles Fa, Micsenyi MC, Cao Y, Venugopal B, Browning MF, Dobrenis K, Cotman SL, Walkley SU, Slaugenhaupt Sa. Macroautophagy is defective in mucolipin-1-deficient mouse neurons. Neurobiol Dis. 2010;40:370–7. doi: 10.1016/j.nbd.2010.06.010. PubMed DOI PMC

Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, Ory DS, Vanier MT, Walkley SU. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One. 2009;4:e6951. doi: 10.1371/journal.pone.0006951. PubMed DOI PMC

Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev. 2007;31:673–704. doi: 10.1016/j.neubiorev.2007.01.005. PubMed DOI

Di Rocco M, Dardis A, Madeo A, Barone R, Fiumara A. Early miglustat therapy in infantile Niemann-Pick disease type C. Pediatr Neurol. 2012;47:40–3. doi: 10.1016/j.pediatrneurol.2012.04.005. PubMed DOI

Dong XP, Cheng X, Mills E, Delling M, Wang F, Kurz T, Xu H. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature. 2008;455:992–6. doi: 10.1038/nature07311. PubMed DOI PMC

Dong X, Wang X, Shen D, Chen S, Liu M, Wang Y, Mills E, Cheng X, Delling M, Xu H. Activating mutations of the TRPML1 channel revealed by proline-scanning mutagenesis. J Biol Chem. 2009;284:32040–52. doi: 10.1074/jbc.M109.037184. PubMed DOI PMC

Edelmann L, Dong J, Desnick RJ, Kornreich R, Amir N, Zlotogora J, Bach G, Bargal R, Avidan N, Ben-Asher E, Olender Z, Zeigler M, Frumkin A, Raas-Rothschild A, Glusman G, Lancet D, Bach G, Bargal R, Avidan N, Olender T, Ben Asher E, Zeigler M, Raas-Rothschild A, Frumkin A, Ben-Yoseph O, Friedlender Y, Lancet D, Bach G, Bargal R, Bach G, Bassi M, Manzoni M, Monti E, Pizzo M, Ballabio A, Borsani G, Berman E, Livni N, Shapira E, Merin S, Levij I, Beutler E, Grabowski G, Chen C, Bach G, Pagano R, Diaz G, Gelb B, Risch N, Nygaard T, Frisch A, Cohen I, Miranda C, Amaral O, Maire I, Poenaru L, Caillaud C, Weizberg M, Mistry P, Desnick R, Dong J, Katz D, Eng C, Kornreich R, Desnick R, Fares H, Greenwald I, Li L, Eng C, Desnick R, German J, Ellis N, Raas-Rothschild A, Bargal R, DellaPergola S, Zeigler M, Bach G, Riedel K, Zwaan J, Kenyon K, Kolodny E, Hanninen L, Albert D, Shuber A, Grondin V, Klinger K, Slaugenhaupt S, Acierno J, Helbling L, Bove C, Goldin E, Bach G, Schiffmann R, Gusella J, Somlo S, Ehrlich B, Sun M, Goldin E, Stahl S, Falardeau J, Kennedy J, Acierno J, Bove C, Kaneski C, Nagle J, Bromley M, Colman M, Schiffmann R, Slaugenhaupt S, Wang Z, Zeng B, Pastores G, Raksadawan N, Ong E, Kolodny E. Carrier Screening for Mucolipidosis Type IV in the American Ashkenazi Jewish Population. Am J Hum Genet. 2002;70:1023–1027. doi: 10.1086/339519. PubMed DOI PMC

Elrick MJ, Pacheco CD, Yu T, Dadgar N, Shakkottai VG, Ware C, Paulson HL, Lieberman AP. Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet. 2010;19:837–47. doi: 10.1093/hmg/ddp552. PubMed DOI PMC

Elstein D, Hollak C, Aerts JMFG, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek Ra, Zimran a. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757–66. doi: 10.1023/B:BOLI.0000045756.54006.17. PubMed DOI

Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res. 1988;31:47–59. PubMed

Goldin E, Caruso RC, Benko W, Kaneski CR, Stahl S, Schiffmann R. Isolated ocular disease is associated with decreased mucolipin-1 channel conductance. Invest Ophthalmol Vis Sci. 2008;49:3134–42. doi: 10.1167/iovs.07-1649. PubMed DOI PMC

Grishchuk Y, Sri S, Rudinskiy N, Ma W, Stember KG, Cottle MW, Sapp E, Difiglia M, Muzikansky A, Betensky RA, Wong AMS, Bacskai BJ, Hyman BT, Kelleher RJ, Cooper JD, Slaugenhaupt SA. Behavioral deficits, early gliosis, dysmyelination and synaptic dysfunction in a mouse model of mucolipidosis IV. Acta Neuropathol Commun. 2014;2:133. doi: 10.1186/s40478-014-0133-7. PubMed DOI PMC

Grösch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res. 2012;51:50–62. doi: 10.1016/j.plipres.2011.11.001. PubMed DOI

Hammer MB, Eleuch-Fayache G, Schottlaender LV, Nehdi H, Gibbs JR, Arepalli SK, Chong SB, Hernandez DG, Sailer A, Liu G, Mistry PK, Cai H, Shrader G, Sassi C, Bouhlal Y, Houlden H, Hentati F, Amouri R, Singleton AB. Mutations in GBA2 Cause Autosomal-Recessive Cerebellar Ataxia with Spasticity. The American Journal of Human Genetics. 2013 doi: 10.1016/j.ajhg.2012.12.012. PubMed DOI PMC

Hůlková H, Ledvinová J, Kuchař L, Šmíd F, Honzíková J, Elleder M. Glycosphingolipid profile of the apical pole of human placental capillaries: the relevancy of the observed data to Fabry disease. Glycobiology. 2012;22:725–32. doi: 10.1093/glycob/cws050. PubMed DOI

Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH, Dwek RA, Platt FM. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci. 1999;96:6388–6393. doi: 10.1073/pnas.96.11.6388. PubMed DOI PMC

Ko DC, Milenkovic L, Beier SM, Manuel H, Buchanan J, Scott MP. Cell-Autonomous Death of Cerebellar Purkinje Neurons with Autophagy in Niemann-Pick Type C Disease. PLoS Genet. 2005;1:e7. doi: 10.1371/journal.pgen.0010007. PubMed DOI PMC

Kuchar L, Ledvinová J, Hrebícek M, Mysková H, Dvoráková L, Berná L, Chrastina P, Asfaw B, Elleder M, Petermöller M, Mayrhofer H, Staudt M, Krägeloh-Mann I, Paton BC, Harzer K. Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations. Am J Med Genet A. 2009;149A:613–21. doi: 10.1002/ajmg.a.32712. PubMed DOI PMC

Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross Ra, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187–91. doi: 10.1038/nature11556. PubMed DOI PMC

LaPlante JM, Sun M, Falardeau J, Dai D, Brown EM, Slaugenhaupt Sa, Vassilev PM. Lysosomal exocytosis is impaired in mucolipidosis type IV. Mol Genet Metab. 2006;89:339–48. doi: 10.1016/j.ymgme.2006.05.016. PubMed DOI

Lau AA, Crawley AC, Hopwood JJ, Hemsley KM. Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behav Brain Res. 2008;191:130–136. doi: 10.1016/j.bbr.2008.03.024. PubMed DOI

Lima WC, Leuba F, Soldati T, Cosson P. Mucolipin controls lysosome exocytosis in Dictyostelium. J Cell Sci. 2012;125:2315–2322. PubMed

Loberto N, Tebon M, Lampronti I, Marchetti N, Aureli M, Bassi R, Giri MG, Bezzerri V, Lovato V, Cantù C, Munari S, Cheng SH, Cavazzini A, Gambari R, Sonnino S, Cabrini G, Dechecchi MC. GBA2-encoded β-glucosidase activity is involved in the inflammatory response to Pseudomonas aeruginosa. PLoS One. 2014;9:e104763. doi: 10.1371/journal.pone.0104763. PubMed DOI PMC

Marques ARa, Aten J, Ottenhoff R, Van Roomen CPaa, Moro DH, Claessen N, Veloz MFV, Zhou K, Lin Z, Mirzaian M, Boot RG, De Zeeuw CI, Overkleeft HS, Yildiz Y, Aerts JMFG. Reducing GBA2 activity ameliorates neuropathology in niemann-pick type C mice. PLoS One. 2015;10:1–18. doi: 10.1371/journal.pone.0135889. PubMed DOI PMC

Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, Allaire A, Cromwell MA, Wang B, Grabowski GA, Leonard JP, Cheng SH. CNS-Accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease. Mol Ther. 2016 doi: 10.1038/mt.2016.53. PubMed DOI PMC

McGlynn R, Dobrenis K, Walkley SU. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol. 2004;480:415–426. doi: 10.1002/cne.20355. PubMed DOI

Medina DL, Di Paola S, Peluso I, Armani A, De Stefani D, Venditti R, Montefusco S, Scotto-Rosato A, Prezioso C, Forrester A, Settembre C, Wang W, Gao Q, Xu H, Sandri M, Rizzuto R, De Matteis MA, Ballabio A. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol. 2015;17:288–299. doi: 10.1038/ncb3114. PubMed DOI PMC

Micsenyi M, Dobrenis K, Stephney G, Pickel J, Vanier M, Slaugenhaupt S, Walkley S. Neuropathology of the Mcoln1 −/− knockout mouse model of mucolipidosis type IV. J Neuropathol Exp Neurol. 2009;68:125–135. PubMed PMC

Natomi H, Sugano K, Iwamori M, Takaku F, Nagai Y. Region-specific distribution of glycosphingolipids in the rabbit gastrointestinal tract: preferential enrichment of sulfoglycolipids in the mucosal regions exposed to acid. Biochim Biophys Acta. 1988;961:213–22. PubMed

Pastores GM. Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov. 2006;1:77–82. PubMed

Pastores GM, Barnett NL. Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin Investig Drugs. 2003;12:273–81. doi: 10.1517/13543784.12.2.273. PubMed DOI

Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6:765–72. doi: 10.1016/S1474-4422(07)70194-1. PubMed DOI

Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269:8362–5. PubMed

Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD, Neufeld EF, Beutler E, Barton NW, Beutler E, Platt FM, Neises GR, Dwek RA, Butters TD, Platt FM, Butters TD, Yamanaka S, Sango K, Taniike M, Fischl MA. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997a;276:428–31. doi: 10.1126/science.276.5311.428. PubMed DOI

Platt FM, Reinkensmeier G, Dwek RA, Butters TD. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem. 1997b;272:19365–72. PubMed

Ridley CM, Thur KE, Shanahan J, Thillaiappan NB, Shen A, Uhl K, Walden CM, Rahim Aa, Waddington SN, Platt FM, Van Der Spoel AC. β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J Biol Chem. 2013;288:26052–26066. doi: 10.1074/jbc.M113.463562. PubMed DOI PMC

Sarna JR, Hawkes R. Patterned Purkinje cell death in the cerebellum. Prog Neurobiol. 2003;70:473–507. doi: 10.1016/S0301-0082(03)00114-X. PubMed DOI

Schaheen L, Dang H, Fares H. Basis of lethality in C. elegans lacking CUP-5, the Mucolipidosis Type IV orthologue. Dev Biol. 2006;293:382–91. doi: 10.1016/j.ydbio.2006.02.008. PubMed DOI

Schiffmann R, Mayfield J, Swift C, Nestrasil I. Quantitative neuroimaging in mucolipidosis type IV. Mol Genet Metab. 2014;111:147–51. doi: 10.1016/j.ymgme.2013.11.007. PubMed DOI PMC

Sillitoe RV, Joyner AL. Morphology, molecular codes, and circuitry produce the three-dimensional complexity of the cerebellum. Annu Rev Cell Dev Biol. 2007;23:549–77. doi: 10.1146/annurev.cellbio.23.090506.123237. PubMed DOI

Slaugenhaupt SA, Acierno JS, Jr, Helbling LA, Bove C, Goldin E, Bach G, Schiffmann R, Gusella JF, Amir N, Zlotogora J, Bach G, Anderson M, Gusella J, Bach G, Zeigler M, Bargal R, Bargal R, Bach G, Berman E, Livni N, Shapira E, Merin S, Levij I, Chen C, Bach G, Pagano R, Cottingham R, Idury R, Schaffer A, Crandall B, Philippart M, Brown W, Bluestone D, Lathrop G, Lalouel J, Lathrop G, Lalouel J, Julier C, Ott J, Lathrop G, Lalouel J, White R, Ott J, Schaffer A, Schaffer A, Gupta S, Shriram K, Cottingham R, Schiffman R, Dwyer N, Lubensky I, Tsokos M, Sutliff V, Latimer J, Frei K, Weeks D, Ott J, Lathrop G, et al. Mapping of the Mucolipidosis Type IV Gene to Chromosome 19p and Definition of Founder Haplotypes. Am J Hum Genet. 1999;65:773–778. doi: 10.1086/302549. PubMed DOI PMC

Soyombo Aa, Tjon-Kon-Sang S, Rbaibi Y, Bashllari E, Bisceglia J, Muallem S, Kiselyov K. TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity. J Biol Chem. 2006;281:7294–301. doi: 10.1074/jbc.M508211200. PubMed DOI

Sprott RL, Eleftheriou BE. Open-Field Behavior in Aging Inbred Mice. Gerontology. 2009;20:155–162. doi: 10.1159/000212009. PubMed DOI

Stanley JL, Lincoln RJ, Brown TA, McDonald LM, Dawson GR, Reynolds DS. The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. J Psychopharmacol. 2005;19:221–7. doi: 10.1177/0269881105051524. PubMed DOI

Stein VM, Crooks A, Ding W, Prociuk M, O’Donnell P, Bryan C, Sikora T, Dingemanse J, Vanier MT, Walkley SU, Vite CH. Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. J Neuropathol Exp Neurol. 2012;71:434–48. doi: 10.1097/NEN.0b013e31825414a6. PubMed DOI PMC

Sun M, Goldin E, Stahl S, Falardeau JL, Kennedy JC, Jr, A JS, Bove C, Kaneski CR, Nagle J, Bromley MC, Colman M, Schiffmann R, Slaugenhaupt SA. Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. 2000;9:2471–2478. PubMed

Tallaksen CME, Berg JE. Miglustat therapy in juvenile Sandhoff disease. J Inherit Metab Dis. 2009;32:289–293. doi: 10.1007/s10545-009-1224-7. PubMed DOI

Tellez-Nagel I, Rapin I, Iwamoto T, Johnson A, Norton W, Nitowsky H. Mucolipidosis IV: Clinical, Ultrastructural, Histochemical, and Chemical Studies of a Case, Including a Brain Biopsy. Arch Neurol. 1976;33:828–835. PubMed

Venkatachalam K, Long AA, Elsaesser R, Nikolaeva D, Broadie K, Montell C. Motor deficit in a Drosophila model of mucolipidosis type IV due to defective clearance of apoptotic cells. Cell. 2008;135:838–51. doi: 10.1016/j.cell.2008.09.041. PubMed DOI PMC

Venugopal B, Browning M, Curcio-Morelli C, Varro A, Michaud N, Nanthakumar N, Walkley S, Pickel J, Slaugenhaupt S. Neurologic, gastric, and opthalmologic pathologies in a murine model of mucolipodosis type IV. Am J Hum Genet. 2007;81:1070–1083. doi: 10.1086/521954. PubMed DOI PMC

Wakabayashi K, Gustafson AM, Sidransky E, Goldin E. Mucolipidosis type IV: an update. Mol Genet Metab. 2011;104:206–13. doi: 10.1016/j.ymgme.2011.06.006. PubMed DOI PMC

Wong CO, Palmieri M, Li J, Akhmedov D, Chao Y, Broadhead GT, Zhu MX, Berdeaux R, Collins CA, Sardiello M, Venkatachalam K. Diminished MTORC1-Dependent JNK Activation Underlies the Neurodevelopmental Defects Associated with Lysosomal Dysfunction. Cell Rep. 2015;12:2009–2020. doi: 10.1016/j.celrep.2015.08.047. PubMed DOI PMC

Wortmann SB, Lefeber DJ, Dekomien G, Willemsen MAAP, Wevers RA, Morava E. Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab Dis. 2009;32:307–311. doi: 10.1007/s10545-009-1261-2. PubMed DOI

Ye CP, Quinn SJ, Goldin E, Brown EM, Slaugenhaupt S, Vassilev PM. Functional links between mucolipin-1 and Ca2+ - dependent membrane trafficking in mucolipidosis IV. Biochem Biophys Res Commun. 2004;322:1384–1391. PubMed

Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol. 2001a;60:49–64. PubMed

Zervas M, Somers KL, Thrall Ma, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 2001b;11:1283–7. PubMed

Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function